Glucose control and cardiovascular outcomes: Reorienting approach

Cardiovascular disease accounts for nearly 70 % of morbidity and mortality in patients with diabetes mellitus. Strides made in diabetes care have indeed helped prevent or reduce the burden of microvascular complications in both type-1 and type-2 diabetes. However, the same can’t be said about macrov...

Full description

Bibliographic Details
Main Authors: Romesh eKhardori, Diep eNguyen
Format: Article
Language:English
Published: Frontiers Media S.A. 2012-08-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00110/full
id doaj-50ce9464115b4b64ae75c99898175436
record_format Article
spelling doaj-50ce9464115b4b64ae75c998981754362020-11-24T21:24:54ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922012-08-01310.3389/fendo.2012.0011031845Glucose control and cardiovascular outcomes: Reorienting approachRomesh eKhardori0Diep eNguyen1Eastern Virginia Medical SchoolEastern Virginia Medical SchoolCardiovascular disease accounts for nearly 70 % of morbidity and mortality in patients with diabetes mellitus. Strides made in diabetes care have indeed helped prevent or reduce the burden of microvascular complications in both type-1 and type-2 diabetes. However, the same can’t be said about macrovascular disease in diabetes. Several prospective trials so far have failed to provide conclusive evidence of glycemic control superiority in reducing macrovascular complications or death rate in people with advanced disease or those with long duration of diabetes. There are trends that suggest that benefits are restricted to those with lesser burden and shorter duration of disease. Furthermore, it is also suggested that benefits might accrue but it would take longer time to manifest. Clinicians are fraught with challenge to decide how to triage patients for intensified care versus less intense care. This review focusses on evidence and attempts to provide a balanced view of literature that has radically affected how physicians treat patients with macrovascular disease. It also takes cognizance of the fact that natural course of disease may be changing as well possibly related to better overall awareness and possibly improved access to information about better individual healthcare. The review further takes note of some hard held notions about pathobiology of disease that must be interpreted with caution in light of new emerging data. In light of recent developments ADA and EASD have taken step to provide some guidance to clinicians through a joint position statement. A lot more research would be required to figure out how best to manage macrovascular disease in diabetes mellitus. Glucocentric stance would have to yield to evidence based, and possibly, concurrent multifactorial intervention to enhance quality of care that is safe and effective.http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00110/fullInsulindiabetesTreatmentHeart diseaseTight Control
collection DOAJ
language English
format Article
sources DOAJ
author Romesh eKhardori
Diep eNguyen
spellingShingle Romesh eKhardori
Diep eNguyen
Glucose control and cardiovascular outcomes: Reorienting approach
Frontiers in Endocrinology
Insulin
diabetes
Treatment
Heart disease
Tight Control
author_facet Romesh eKhardori
Diep eNguyen
author_sort Romesh eKhardori
title Glucose control and cardiovascular outcomes: Reorienting approach
title_short Glucose control and cardiovascular outcomes: Reorienting approach
title_full Glucose control and cardiovascular outcomes: Reorienting approach
title_fullStr Glucose control and cardiovascular outcomes: Reorienting approach
title_full_unstemmed Glucose control and cardiovascular outcomes: Reorienting approach
title_sort glucose control and cardiovascular outcomes: reorienting approach
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2012-08-01
description Cardiovascular disease accounts for nearly 70 % of morbidity and mortality in patients with diabetes mellitus. Strides made in diabetes care have indeed helped prevent or reduce the burden of microvascular complications in both type-1 and type-2 diabetes. However, the same can’t be said about macrovascular disease in diabetes. Several prospective trials so far have failed to provide conclusive evidence of glycemic control superiority in reducing macrovascular complications or death rate in people with advanced disease or those with long duration of diabetes. There are trends that suggest that benefits are restricted to those with lesser burden and shorter duration of disease. Furthermore, it is also suggested that benefits might accrue but it would take longer time to manifest. Clinicians are fraught with challenge to decide how to triage patients for intensified care versus less intense care. This review focusses on evidence and attempts to provide a balanced view of literature that has radically affected how physicians treat patients with macrovascular disease. It also takes cognizance of the fact that natural course of disease may be changing as well possibly related to better overall awareness and possibly improved access to information about better individual healthcare. The review further takes note of some hard held notions about pathobiology of disease that must be interpreted with caution in light of new emerging data. In light of recent developments ADA and EASD have taken step to provide some guidance to clinicians through a joint position statement. A lot more research would be required to figure out how best to manage macrovascular disease in diabetes mellitus. Glucocentric stance would have to yield to evidence based, and possibly, concurrent multifactorial intervention to enhance quality of care that is safe and effective.
topic Insulin
diabetes
Treatment
Heart disease
Tight Control
url http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00110/full
work_keys_str_mv AT romeshekhardori glucosecontrolandcardiovascularoutcomesreorientingapproach
AT diepenguyen glucosecontrolandcardiovascularoutcomesreorientingapproach
_version_ 1725986205470818304